(Q38010377)

26 August 2017

title

Development of treatment strategies for advanced neuroblastoma (English)

1 reference

26 August 2017

Junichi Hara

1

1 reference

26 August 2017

publication date

16 May 2012

1 reference

International Journal of Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

17

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

196-203

1 reference

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

How frequent is spontaneous remission of neuroblastomas? Implications for screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A Phase I Study of Irinotecan As a 3-Week Schedule in Children With Refractory or Recurrent Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Retinoid therapy of high-risk neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Disialoganglioside directed immunotherapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Polo-like kinases and the orchestration of cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Finding the weakness in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Translocations involving anaplastic lymphoma kinase (ALK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Expression of the ALK tyrosine kinase gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0417-5

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 January 2018

1 reference

12 December 2020

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

1 reference

12 December 2020

A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age

1 reference

12 December 2020

Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984

1 reference

12 December 2020

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

1 reference

12 December 2020

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

1 reference

12 December 2020

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

1 reference

12 December 2020

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.

1 reference

12 December 2020

Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro.

1 reference

12 December 2020

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

12 December 2020

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

12 December 2020

Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis

1 reference

12 December 2020

Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3

1 reference

12 December 2020

Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway

1 reference

12 December 2020

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study

1 reference

12 December 2020

Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1

1 reference

12 December 2020

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

12 December 2020

Spontaneous regression of localized neuroblastoma detected by mass screening

1 reference

12 December 2020

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth

1 reference

12 December 2020

10.1007/S10147-012-0417-5

Identifiers

DOI

1 reference

26 August 2017

1 reference